Lissencephaly comprises a spectrum of brain malformations due to impaired neuronal migration in the developing cerebral cortex. Classical lissencephaly is characterized by smooth cerebral surface and cortical thickening that result in seizures, severe neurological impairment and developmental delay. Mutations in the X-chromosomal gene DCX, encoding doublecortin, is the main cause of classical lissencephaly. Much of our knowledge about DCX-associated lissencephaly comes from post-mortem analyses of patient's brains, mainly since animal models with DCX mutations do not mimic the disease. In the absence of relevant animal models and patient brain specimens, we took advantage of induced pluripotent stem cell (iPSC) technology to model the disease. We established human iPSCs from two males with mutated DCX and classical lissencephaly including smooth brain and abnormal cortical morphology. The disease was recapitulated by differentiation of iPSC into neural cells followed by expression profiling and dissection of DCX-associated functions. Here we show that neural stem cells, with absent or reduced DCX protein expression, exhibit impaired migration, delayed differentiation and deficient neurite formation. Hence, the patient-derived iPSCs and neural stem cells provide a system to further unravel the functions of DCX in normal development and disease.
INTRODUCTION
Development of the human cortex starts at gestational week 5 through mitosis of neural stem cells in the ventricular zone followed by radial migration of cells towards the cortical plate. 1, 2 Several genes have shown to be critical in this process and mutation in any of the LIS1, DCX, TUBA1A, VLDLR, ARX and RELN genes may cause a neuronal migration disorder. [3] [4] [5] Mutations in the DCX gene are the major cause of classical lissencephaly, a severe cortical malformation characterized by unfolded, smooth brain, and cortical thickening. DCX is a brain-specific microtubuleassociated protein present in migrating neuroblasts and regulates neuronal migration by promoting microtubule polymerization and stabilization. [6] [7] [8] The DCX protein consists of several regions including the two evolutionary conserved doublecortin-like domains involved in DCX's binding to microtubules. 9 Different mutations in these domains have been associated with neuronal migration disorders lissencephaly and subcortical band heterotopia, that is, double cortex. 10 The DCX gene is situated on the X-chromosome and causes classical lissencephaly in males.
Along with neuroblast migratory defects, recent literature hypothesizes about additional cellular mechanisms underlying the phenotypes found in the brains of patients. 11 Cappello and colleagues suggest a radial glia cause of double cortex, based on experiments in mice where the lack of the GTPase RhoA showed much greater migrational phenotypes when it was genetically removed from radial glia cells than from the developing neurons. Another suggestion about the cellular mechanisms of double cortex has been that deregulated adherens junctions, important for the adhesion of the radial glia cells, cause increased proliferation of the neural stem cells in addition to disturbances in axonal projections. 12 In contrast to humans, the majority of small rodents' brains have an unfolded smooth cerebral morphology, making it difficult to model this aspect of lissencephaly in a precise way. DCX mutant mice have a normal cortex and show normal patterns of neocortical neurogenesis and neuronal migration; however, the hippocampus shows disrupted lamination leading to deficits in learning. 13 In contrast, siRNA inhibition of DCX in rat embryonic cortical slices results in severe defects in neuronal migration. These somewhat opposing results indicate a more complex role for DCX than what we presently appreciate.
14 Along with DCX, there are many additional mechanisms for guiding the migrating neurons and neurites to their targets in the brain, including the Slit/Robo system. 15 Here, we have generated patient-specific induced pluripotent stem cells (iPSCs) to derive a cellular model for our study. We reported mis-regulations of migration, neurite outgrowth and differentiation by DCX-mutated, patient-specific iPSC-derived neural progenitors. Our lissencephaly model revealed that proper DCX function was key, not only for successful cell migration and neurite outgrowth but also for proper initiation of neuronal differentiation, where it appeared that patient cells were partly resistant to differentiation. Transcriptome analysis of differentiating cell cultures agreed with these observations, and several genes linked to neuronal differentiation and migration were deregulated in DCX-deficient cultures such as SLIT/Robo family members. We could rescue the neurite outgrowth phenotype either by knocking down the repellent axon guidance molecule SLIT3 or by applying recombinant Robo1/Robo2 proteins during differentiation.
MATERIALS AND METHODS

Patient imaging
First patient with a DCX-R19Stop mutation was imaged using computer tomography and diagnosed with lissencephaly at 1 month of age. The second patient with a DCX-T88M mutation was analyzed by magnetic resonance imaging and diagnosed with lissencephaly at the age of 4 months.
Reprogramming fibroblasts and iPSC culture Human skin fibroblasts obtained from two lissencephaly patients (DCXR19Stop and DCX-T88M) and two healthy individuals (Ctrl 1 and Ctrl 3) were used to generate iPSC lines as previously described 16 . AF22, a control line, was described elsewhere. 17 Briefly, approximately 100 000 fibroblasts were transduced using a non-integrated method 18 with OCT3/4, KLF4, SOX2 and c-MYC Sendai virus vectors at a multiplicity of infection of 3 (CytoTune-iPS reprogramming kit, Life Technology, Carlsbad, CA, USA). After 1 week, cells were re-plated to irradiated human foreskin fibroblasts (ATCC, CRL-2429, Manassas, VA, USA). Three weeks post-transduction, individual iPSC clones could be manually transferred to separate wells. All iPSC lines were cultured in knock-out DMEM medium supplemented with 20% knockout serum replacement, 1% Pen/Strep, 1% NEAA, 0.1 mM betamercaptoethanol, 1% L-glutamine (all from Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 6 ng ml − l FGF2 (R&D Systems, Minneapolis, MN, USA). Medium was changed daily and iPSC colonies were passaged manually every 5 to 7 days for at least 10 passages before further characterization and differentiations. Written informed consent was obtained from the parents of both patients. This study was approved by the regional ethical committee of Uppsala, Sweden (D-number 319/2009).
PluriTest
For each iPSC line, a feeder free culture was prepared using matrigel (BD, Franklin Lakes, NJ, USA)-coated plates. Total RNA was prepared using the RNeasy kit (Qiagen, Valencia, CA, USA) and quantity and quality were checked by absorbance and Bioanalyzer (Agilent Technologies, RNA 6000 Nano kit, Santa Clara, CA, USA) measurements. Total RNA (200 ng) was amplified to produce the labeled cRNA using Ambion TotalPrep RNA Amplification Kit according to the protocol supplied with the kit. The quantity and quality of the cRNA were checked, and then 800 ng cRNA was used as the template for an Illumina Gene Expression HT12 Direct Hybridization assay. PluriTest contains approximately 450 genome-wide transcriptional profiles from 223 human embryonic stem cells and 41 human iPSC lines. 19 Transcriptome data from our iPSCs were then uploaded to the PluriTest web-portal (www.pluritest.org) for online evaluation.
Generation of NESC lines
To derive long-term self-renewing neuroepithelial-like stem cells (NESCs), iPSC colonies were induced to differentiate to neural tissue and NESC cultures were captured and maintained essentially as previously described, 17 with the following exceptions. Briefly, in monolayer cultures and in the presence of leukemia inhibitory factor, and chemically defined factors, including 3 μM glycogen synthase kinase 3 (GSK3) inhibitor (CHIR99021, Stem molecule), 2 μM transforming growth factor beta receptor inhibitor (SB431542; Sigma-Aldrich, St. Louis, MO, USA), and 2 μM gamma-secretase inhibitor N-(N-(3,5-difluorophenacetyl)-L-alanyl)-Sphenylglycine t-butyl ester (DAPT; Sigma-Aldrich); iPSCs were subjected to neuronal induction for 5 to 7 days. After 3 days, neuronal rosettes appeared; they were manually picked at day 5 to day 7. Rosettes were isolated manually using a pulled pasture pipette and left to float in DMEM/ F12 medium with N 2 supplement (1:100) for 2 days (Invitrogen, Life Technology). Floating rosettes were dissociated in TrypLE-Express (Gibco) to single cells and plated onto 0.1 mg poly-L-ornithine (Sigma-Aldrich) and 1 μg ml − 1 laminin L2020 (Sigma-Aldrich) coated (PLO/L-coated) plates at high density (40 000 cells cm -2 ) in NESC medium (DMEM/F-12, GlutaMAX containing N 2 supplement, FGF2 (10 ng ml − 1 ), B27 (0.1%) and Pen/Strep all from Invitrogen and EGF (10 ng ml
; Peprotech, Rocky Hill, NJ, USA)). Established NESC lines were passaged at the ratio of 1:3 every third day.
Neuronal differentiation of NESC cultures
For neuronal differentiations of NESCs, monolayer cultures with the density of 40 000 cell cm − 2 were grown in differentiation medium (NESC medium without EGF and FGF2). Laminin L2020 (1:1000; Sigma-Aldrich) was applied to the medium twice a week. Cultures were harvested or fixed at indicated time points for downstream characterization.
RNA, DNA and protein extraction and downstream assays Genomic DNA, total RNA and total protein from each sample were extracted by AllPrep mini kit (Qiagen) according to the manufacturer's protocol. An additional DNase I step was performed to remove genomic DNA contamination on RNA columns (Qiagen). Then, 1 μg RNA was converted to cDNA with Superscript III (Invitrogen) according to the manufacturer's protocol. Ten nanograms cDNA was used in fast SYBR Green Master Mix (Life Technologies) using a real-time machine (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA, USA). Threshold cycle (Ct) values of three experimental replicates were analyzed with a relative quantification method using the 2 -ΔΔCt equation according to the reference. 20 For each sample the relative expression of a target gene was normalized to the housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Purified protein samples were quantified using the Qubit kit (Invitrogen). Twenty nanograms protein was loaded to a precast gel (Biorad, Hercules, CA, USA) and run in running buffer (LI-COR Biosciences, Lincoln, NE, USA) at 120 V for 1 h. Proteins on the gel were transferred to a nitrocellulose membrane in a transfer sandwich at 30 V overnight at 4°C. After 1 h blocking in Odyssey blocking buffer, the membrane was exposed to primary antibody at 4°C overnight. Followed by three times washing with Phosphate buffered saline contains 0.1% Tween 20, then incubated in secondary antibody (1:10 000; LI-COR) for 1 h at room temperature. The membrane was washed three times and the image developed in Odyssey Imager (LI-COR).
Immunofluorescence staining Cells were cultured on coated glass coverslips and fixed in 4% paraformaldehyde for 20 min at room temperature and washed with phosphate-buffered saline prior to addition of blocking buffer (phosphatebuffered saline with 0.1% Triton-X, with 1% bovine serum albumin) for 1 h at room temperature. Primary antibodies (Supplementary Table S1 ) were diluted in blocking buffer and were added to the cells for incubation overnight at 4°C. The following day, cells were washed with phosphatebuffered saline and incubated 1 h at room temperature with an appropriate secondary antibody. Secondary antibodies to mouse, rabbit and goat, conjugated with Alexa Flour 488, 546 or 647, were all from Invitrogen and an anti-chicken antibody from Aves Labs were used. Images were taken in a confocal microscope, Zeiss LSM-700 (Carl Zeiss, Oberkochen, Germany).
Quantification of the dendrite bundles of differentiating cells
To quantify microtubule bundles' distribution and diameter, a minimum of 10 fields was randomly captured from each coverslip. The total number of bundles labeled with MAP2 antibody was counted from each field. The diameter of the bundles was measured using ImageJ software (US National Institutes of Health, Bethesda, MD, USA). We used a diameter of 33 μM as a cutoff for the bundles. Results represented as mean ± s.d. of at least three independent coverslips per cell line and non-overlapping randomly selected fields (total 30 fields per line).
Monolayer in vitro migration assay NESC lines were transduced with Lentiviral vector pRRLSIN.cPPT.PGK-GFP. WPRE to be marked with green fluorescent protein (GFP). To monitor individual cells in a migration assay, GFP+ cells and non-transduced cells were mixed at a ratio of 1:100 and then plated onto PLO/L-coated plates. Cells were imaged every seventh day, that is, day 7, 14 and 21 of differentiation. matrigel (diluted 1:10 in differentiation medium, BD) and embedded on coverslips by spreading over the surface and incubated at 37°C, 5% CO 2 for 15 min to solidify the matrigel. Differentiation medium was then added on coverslips and incubated at 37°C, 5% CO 2 . After 24 h, images of neurospheres were captured. Average neurite outgrowth was then calculated by measuring the average length of all neurites (replicates) from each neurosphere (sample), followed by calculating the average length for each cell line.
To rescue the neurite outgrowth deficiency in patient cells, we first found the non-neurotoxic concentration of recombinant DCX (Thermo Fisher Scientific, Waltham, MA, USA), Robo1 (R&D System) and Robo2 (R&D system) in the NESCs. Then we added recombinant DCX (100 ng ml − 1 ), Robo1/2 (1 μg ml − 1 each) to the differentiation medium.
Time-lapse study of migration assay
For making neurospheres, NESCs were plated at 40 000 cells cm − 2 in differentiation medium. After 5 days of differentiation, cells were trypsinized and plated on non-adhesive plates in differentiation medium. The following day, neurospheres of equal size were picked with a cut 200-An in vitro model of lissencephalyμl pipette tip and plated on a PLO/L-coated 24-well plate. Six to eight neurospheres were plated in each well and fresh differentiation medium was added. The plate was placed at 37°C in a Cell-IQ (CM Technologies, Tampere, Finland) and connected to a 5% CO 2 pump, where the neurospheres were imaged every 30 min for 3 days. Analysis was done using ImageJ.
Proliferation and differentiation assays
NESCs were plated at a density of 100 000 cells in each well of a 12-well plate and cultured in NESC medium or differentiation medium for proliferation and differentiation counting assays, respectively. For the proliferation assay, cells were counted on days 2, 4 and 6 in triplicates. For the differentiation assay, cells were counted on days 3, 6, 9, 12 and 15 in triplicates using a MOXI Z automated cell counter.
Transcriptome analysis
Transcriptional analysis was done on RNA collected from cell lines at four time points of differentiation: day 0 (proliferating NESCs), 7, 14 and 21. RNA extraction and cDNA conversion were done as above and subsequent transcriptome microarray analyses were performed on Affymetrix HTA2.0 array at the BEA (Bioinformatics and Expression Analysis) core facility (Stockholm, Sweden). Raw data from scanning were pre-processed in Affymetrix Expression Console using the RMA (Robust Multi-Array)-method. To increase the statistical power in our further analyses, we grouped the differentiation time points (7, 14, 21 days) of the two patient NESC lines and the two control NESC lines; only genes on the autosomal chromosomes were analyzed.
Gene ontology analysis
Lists of differentially expressed genes (P adj o 0.05) in patients' differentiating neurons were analyzed with the PANTHER (protein annotation through evolutionary relationship) 21, 22 statistical overrepresentation test for Gene Ontology (GO) term. GO terms for axon guidance (GO:0007411), cell adhesion (GO:0007155), regulation of cell proliferation (GO:0042127), cell migration (GO:0016477) and neuron development (GO:0048666) were chosen for representation of phenotypic observations.
Venn diagram
Upregulated genes (Po0.05) in patient neurons used in the PANTHER overrepresentation test for corresponding GO terms were used for plotting a Venn diagram with Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/).
STRING Network
Network generation with confidence score of 0.4 was used for predicted associated protein-protein interactions with STRING 10.0 (http://string-db. org) using six common genes (GATA3, HES4, ITGAV, KITLG, NTN1, SRC with addition of NOTCH1) and five additional interactors. 23 
Statistical analysis
Statistical analyses were performed using R and SPSS with one-way ANOVA followed by Tukey's post hoc test. Data were presented as mean ± s.e.m. and a value of Po 0.05 was considered as statistically significant. In the analysis of differentially expressed genes between lissencephaly and control groups, the data set was germ line subtracted. Table S2 ) were reprogrammed and used for further neural induction and differentiation as shown schematically in Figure 1a . Both patients showed a smooth cortex without gyri visualized by computer tomography at 1 month of age (DCXR19Stop, Figure 1b Figure S1a) . A thorough characterization of the iPSC line Ctrl 3 has been published elsewhere 16 . Here the iPSC lines Ctrl 1, DCX-R19Stop and DCX-T88M were tested for pluripotency by ICC and stained positive for the cell surface markers Tra1-60 and Tra-81 as well as the nuclei markers Oct4 and Nanog (Supplementary Figure S1b) . To further assess the pluripotency of the iPSCs, we investigated their gene expression profiles with the Taqman Low Density Array (TLDA Human Stem Cell Pluripotency Panel) (ABI, Thermo Fisher Scientific, Carlsbad, CA, USA) for Ctrl 1 and the PluriTest tool 19 for Ctrl 3 and the two patient lines. Transcriptional profiling showed that the Ctrl 1 iPSC line was pluripotent, with high expression of pluripotency and stemness marker genes, whereas no or only low signals from lineage-specific genes were detected (data not shown). All iPSC lines passed the PluriTest with low novelty, indicating a low degree of heterogeneity and high pluripotency score (Supplementary Figure S1c) . Overall, we did not observe any differences between patient and control samples in the derivation of iPSC lines, and our characterization provides evidence that the iPSC lines derived from all subjects are reprogrammed to pluripotency with a potential to differentiate into all three germ layers (embryoid body analysis, data not shown).
RESULTS
Derivation and characterization of iPSC and NESC lines from lissencephaly patients and control samples Fibroblasts from two patients and two control cell lines (Supplementary
No noticeable differences were observed in the ability to establish NESC lines from the different iPSC lines. The NESCs self-organize into rosette-like structures with apical interaction between the cells and all NESC lines expressed the typical neural stem cell markers NESTIN, SOX2 and PAX6 (Supplementary Figure S1d) . We assessed the neurogenic potential of the NESC lines using non-directed differentiation by removing the growth factors EGF and FGF2 from the medium. All differentiating cultures displayed a large proportion of cells expressing the neuronal markers β-III-tubulin and microtubuleassociated protein 2 (MAP2) (Supplementary Figure S1e) , demonstrating their capacity to produce neurons. Interestingly, we repeatedly noticed an altered distribution of MAP2 in our immunostainings on differentiated cultures. Although DCX-deficient lines appeared to differentiate to a high degree of neuronal cells, they appeared to form less pronounced bundles of MAP2+ cell extensions (Supplementary Figure S1e) .
DCX expression is regulated during neuronal differentiation in vitro
To reveal the DCX expression profile in healthy and patient lines, all NESC lines were induced to non-directed differentiation. qPCR data showed that the expression of DCX at mRNA level was upregulated dramatically in all cell lines during the first 7 days (Figure 1e ). ICC analysis indicated that NESCs in the proliferative conditions expressed limited or no DCX protein (Figure 1d 
Lissencephaly-derived neuronal cultures have reduced number and thickness of dendrite bundles
To further analyze the observed differences in MAP2 distribution as a major neural cytoskeletal protein, we repeated the differentiation experiment and could confirm a reduced degree of bundling in DCX-deficient neurons from both patients by ICC at day 14 of differentiation (Figures 1g-i) . To quantify the degree of bundling reduction, we manually counted the number of bundles and the corresponding diameter per area unit and found a threefold reduction in number of bundles in neuronal differentiation cultures of patient neurons as compared with control differentiating neurons (Figure 1h ). We found a similar average diameter of bundles in control lines, Ctrl1 and Ctrl3, whereas a significant difference was found when compared with the patients' differentiating neurons (Figure 1i ). DCX-T88M culture revealed fewer bundles with lesser thickness compared with the DCX-R19Stop culture (Figure 1i ).
Transcriptome analysis of control and disease cell cultures during neuronal differentiation Transcriptional similarity on hierarchical cluster diagram indicated three main clusters of differentiation day 0 (proliferating NESCs), 7, 14 and 21 of patient (DCX-R19Stop and DCX-T88M) and control (Ctrl 1 and AF22) cell lines: (i) proliferating NESC lines from both patients and controls, (ii) differentiated control lines and (iii) differentiated patient lines (Figure 2a) . The common cluster with NESC lines from both groups indicated high similarity between lines regardless of mutated or normal DCX gene. This finding is in line with our analyses of iPSCs and NESCs; when DCX was not expressed, cell lines from both groups displayed similar characteristics. However, during neuronal differentiation (days 7-21), when DCX was expressed, patient and control cells clustered in two separate groups away from the NESC cluster (Figure 2a Numbers in top left and right corners indicate number of genes with significantly (P o0.05) differential expression, upregulated (red) or downregulated (blue) genes in patients relative to those in healthy subjects. Gray data points are nonsignificant (NS) genes. Vertical lines at estimate ± 1 indicate highly DE genes (log2fc40.58). (Figure 2b ), where separation on PC1 reflected the cell lines' maturation status, with NESCs at one end of the spectra and more differentiated samples at the other. Interestingly, samples from DCX-deficient lines at days 7 and 14 had not separated as far from NESCs as samples from control lines at corresponding time points. Instead, patient-derived samples from day 21 scored similar on PC1 as control samples from days 7 and 14. Samples from the analyzed time points aligned into four groups (0, 7, 14 and 21 days of differentiation), as indicated by dotted lines in Figure 2b . PC2 separated differentiated samples from either cohort, with DCXdeficient samples scoring higher (in the purple area) than control lines (in white area) at days 7, 14 and 21 of differentiation. Again, proliferating NESCs (day 0) were not separated according to group on either PC1 or PC2. Hence, the principal component analysis was in accordance with, and reflected, the clustering analysis (Figure 2a) , where NESC lines in proliferative conditions were more similar between groups than cultures during differentiation. We extracted general NESC markers such as NESTIN, SOX2, PLZF, DACH1, PAX6 and MMNR1 from our transcriptome data set and found similar expression levels between control and patient cells at NESC stage (Supplementary Figure S2a) . To identify differentially expressed (DE) genes between lissencephaly patient and control neural cells (Figure 2c) , we compared the transcriptome data by additional bioinformatics analyses. As the transcriptomic profiles were similar between patient and control NESC cultures, we reasoned that any DE genes at this point would not relate to DCX mutations. Based on principal component analysis and hierarchical cluster analyses (Figures 2a and b) , we divided samples from the differentiation time points (d7-21) into two groups to increase the statistical power: diff control and diff patient. With the P o0.05 cutoff, the DE analysis yielded a long list of genes being either upregulated (4367) or downregulated (2421) (Figure 2c, Supplementary Figures S2b and c and Supplementary Excel File). Among DE genes, using a threshold level at 1 log2 fold change (log2 fc) we identified many genes that were highly relevant and interesting (Supplementary Tables S3 and S4 and Supplementary Figure S2c-g ), such as RELN, BMP5, several HOX family members, adhesion molecules including ICAM1 and ICAM5, and cadherins (CDH3, CDH4, CDH13, CDH15, CDH16, CDH17, CDH20, CDH22, CDH23, CDH24 and CDH26).
DCX-mutated patient neuroblast cells exhibit a migration phenotype As lissencephaly is classified in migrational disorders, we monitored locomotion in mixed GFP+/non-labeled cells (1:100) in Ctrl 1 and DCX-R19Stop cell lines during differentiation. A reduced migration of DCX-deficient cells was apparent as early as day 7. The difference between lines became more pronounced (Figure 3a , top panel) indicated that DCX-deficient cells resided in the area adjacent to where they were originally seeded. In contrast, at day 21, control cells were evenly distributed and roughly covered an area four times larger than the DCX-deficient cell line (Figure 3a) . The videos from time-lapse microscopy on neurospheres over 1 week of differentiation also revealed a deregulated migration phenotype of DCX-R19Stop patient neuroblasts (Supplementary Videos S1 and S2). Patient neuroblast cells retained proliferation and only a few migrated away from the neurosphere. In contrast, control cells migrated quickly and formed an evident neuronal network. These results indicated that DCX-mutated patient neuroblasts migrated less and showed a delay in the differentiation process compared with control neuroblast cells. To confirm these observations, we collected neurospheres at day 6 of differentiation and transferred to laminin-coated wells for continued differentiation as attached spheres in a time-lapse study. By measuring the average radius of cell somas residing in the migratory front, indicated by arrowheads in Figure 3b , we found that DCX-deficient cells migrated less compared with controls. The expansion of the migratory front at day 3, relative to day 0, was 2.2-fold for controls compared with 1.8-fold for the cell lines derived from lissencephaly patients, corresponding to a 20% reduction (Figure 3c and Supplementary Figure S3a) . Shorter neurites sprouted by lissencephaly patients' cells can be rescued by SLIT3 knockdown and treatment with recombinant Robo1/Robo2 proteins To investigate the neurite outgrowth in patient and control neurons, we performed an assay using differentiating neurospheres of patient and control samples (schematic outline, Figure 1a ) and the mean neurite length was quantified (Supplementary Figures S3b and c) . Patient's neurons had an average neurite length that was half the length of the neurites of the control neurons (Supplementary Figure S3c) . To investigate the cause behind the shorter neurites, we investigated our transcriptome data for genes deregulated in the patient samples that was already known to have a function in migration and neurite outgrowth and found that the gene SLIT3 was upregulated in patient neuronal cells compared with control cells during differentiation (Supplementary Figure S3d) . By using shRNA An in vitro model of lissencephalyconstruct, we knocked down the expression of SLIT3 in the two patient NESC lines before performing the neurite outgrowth assay. Interestingly, reducing the levels of SLIT3 rescued the aberrant neurite outgrowth of the patient's neural cells to a level of significance (Po 0.001) (Figure 3d) .
To confirm that the neurite outgrowth inhibition was mediated by SLIT3 and its interaction with Robo receptors, we applied recombinant Robo1 and Robo2. Exogenously applied Robo acts as a ligand trap that sequesters SLIT3, and thus would prevent SLIT3 protein from binding to the endogenous Robo receptors expressed in neurospheres. Indeed, DCX-R19Stop and DCX-T88M neurite outgrowth was no longer inhibited when we added recombinant Robo1 and Robo2 to the medium (Figure 3e) . We also treated the neurospheres with recombinant DCX protein and observed a significant (P o 0.001) increase in neurite outgrowth in both control cell lines. In patient's neurospheres, there was only a trend of increased neurites; however, no significant difference when compared with untreated condition (Figure 3f ). DCX-deficient neuronal progenitor cells display a prolonged proliferation phenotype upon neuronal differentiation During the differentiation and migration experiments, we consistently observed phenotypes of the two patient cells that appeared to reveal a deficiency in differentiation. To assess the proliferation rate of control and patient NESCs during nondirected differentiation, we initially plated the same number of cells and then counted them at each time interval. Our results showed that DCX-mutated patient cells increased more in cell number and for a longer period than control cells after growth factor withdrawal (Figure 4a and Supplementary Figure S3e) . After 2 weeks of differentiation, the numbers of cells in DCX-deficient cultures were almost double compared with control cells (Supplementary Figure S3e, days 12 and 15) . We further analyzed the continued proliferation of the patient cells by quantifying cells expressing the proliferation marker Ki67 during the course of differentiation (Figure 4a ). At the start of differentiation, over 91% of both the control and patient NESCs expressed Ki67 whereas after 14 days of differentiation only 43% and 36% of the Ctrl 1 and Ctrl 3 cell lines, respectively, stained positive for Ki67; in contrast, around 55% of the patient cells expressed Ki67 (Figure 4b and Supplementary Figure S3f) . Since many of the DE genes were associated with various cell functions, we followed up using a GO analysis to identify highly represented GO terms (Figures 4c and d) . Interestingly, within the set of DE genes, GO terms for biological processes involved in cellular migration, neuronal differentiation and axonal outgrowth in addition to cell proliferation and cell adhesion were highly enriched. Downregulated genes associated with axon guidance were most pronounced in fold enrichment (Figure 4c ). In addition to common GO terms for up-and downregulated genes, we analyzed the upregulated genes and found genes associated with cell adhesion to be one of the significant descriptive GO terms (Figure 4d ). Plotting upregulated genes from GO term analysis into a Venn diagram, we identified six genes (GATA3, HES4, ITGAV, KITLG, NTN1, SRC) in common for all GO terms: cell adhesion, cell proliferation, cell migration and neuron development (Figure 4e ). To identify potential key regulators for genes common between GO terms, we generated a STRING network for predicted proteinprotein interactions. In the network, we observed Notch and SRC as central nodes for the six common genes. The upregulation of Notch1 and SRC in the patient samples during differentiation suggested altered decision by the NESCs between proliferation and differentiation (Figure 4f) , as a result of improper DCX function during neuronal differentiation.
DISCUSSION
Malformations of cortical development with genetic 24 or environmental causes (i.e., ZIKA virus 25 ) will lead to abnormal cellular proliferation and migration. Establishment of cellular models that recapitulate early events of human central nervous system development will provide refined insight into the disease mechanisms with the aim to rescue the phenotype. Here we utilized iPSC technology to reprogram fibroblasts from two patients affected by DCX associated lissencephaly followed by neural induction and captured of neural stem cells (NESCs) to compare cellular aspects of proliferation, differentiation and migration, between neural cells with mutated DCX and those with functional DCX protein. Since DCX expression is restricted to neuronal cells during early differentiation and is not expressed in proliferating iPSCs or NESCs, 26 the reprogramming and subsequent culture and characterizations of proliferating iPSC and NESC lines did not display any DCX-related differences between patient and control cell lines. However, several deviations in DCX-deficient cell lines appeared during the early phase of neuronal differentiation. According to ICC analysis, cell lines with mutated DCX failed to produce DCX protein in a normal way and displayed a delayed differentiation along with a prolonged proliferation compared with controls. DCX as a microtubule polymerizing and stabilizing protein is considered to affect migrating neuroblasts; however, here for we believe the first time we have reported that by counting proliferating cells during the differentiation course, it was clear that lissencephaly lines remained more proliferative during the period when differentiation was initiated by removal of growth factors. Among the genes involved in lissencephaly, LIS1 does not only function in neuroblast migration but it is also required for cellular proliferation 27 and neural stem cell division. 28, 29 Moreover, mutation in ARX gene is involved in decreased neural proliferation. 30 In our study also, from around day 14 of differentiation, when DCX mRNA was abundantly upregulated, the differences between patient and control group were most apparent. Our data suggest that the lack of functional DCX protein in patient NESCs caused delayed cell cycle exit compared with healthy control cells. Abnormal proliferation has previously been shown in a microlissencephaly iPSCs model of p80-mutant patient's brain organoids. 31 More recently threedimensional differentiation of human iPSCs in Miller-Dieker syndrome model indicated specific mitotic defects in outer Radioglial (oRG) cells with increased horizontal cleavage angles. 32 To get a wider view of this complex transition from NESCs to neuronal cell types, we investigated the transcriptomes of differentiating cell cultures every 7 days for 3 weeks. In line with our previous experiments showing no disease phenotypes in proliferating NESCs (day 0), transcriptional profiles were very similar between control and patient groups, at a point when DCX is not expressed. However, at all differentiation time points (days 7-21) analyzed, the differences were clear and, in a hierarchical cluster, patient and control lines clustered in separate groups. A similar pattern appeared in a principal component analysis; cells were separated according to the stage of differentiation, and samples that were collected at the three time points during differentiation (days 7, 14 and 21) aligned accordingly, with DCX-deficient cells distinctly separated from control cultures. Interestingly, the largest difference between groups were observed in samples collected at days 7-14 of differentiation, which coincided with upregulation of DCX, suggesting that transcriptional profiles strongly correlated to the cell line's DCX-linked lissencephaly background. Bioinformatics analysis identified several DE genes in samples from patient and control cell lines at differentiation days 7, 14 and 21. Among the identified DE genes, several have been previously described in neurodevelopmental disorders, including lissencephaly. 33 In organoid model investigation of LIS1/YWHAE deletion, it has been indicated that deregulated N-Cadherin play an important role in proliferation and differentiation balance. 34 Interestingly, our GO term analysis suggested enrichment of adhesion molecules, which play role in growth cone-mediated axon guidance, in the set of deregulated genes. For instance, we identified cell adhesion molecule L1-like (CHL1) expression remaining low in DCX-deficient cell lines also during differentiation, whereas it rose dramatically over time in differentiating control lines (Supplementary Figure S2g) . CHL1 is a signal transducer involved in activation of neurite outgrowth, axon growth and cell migration. 35 Interestingly, CHL1 also binds the receptor neuropilin-1, which activates growth cone collapse, and a phosphorylated, cytoplasmic motif of CHL1 binds to DCX. This interaction between phosphorylated CHL1 motif and DCX has been shown to be abolished in lissencephaly mutations of DCX. 36 Since DCX deficiency is associated with default neural migration during corticogenesis, 37 we developed our experimental settings to analyze migration capacities of our patient NESCs during differentiation and neurite formation along with our transcriptome data. Upon starting the neural differentiation and growth factor removal, NESCs lose their rosette-like morphology and increase the level of DCX, which further stimulates bundling and nucleation of microtubules. 38 However, patient cell lines with mutated DCX showed a proliferation delay (described earlier), were they maintained the rosette-like morphology and failed to form thick and elongated microtubule bundles to the same extent as control cells. The thin MAP2 expressing bundles in patient cell lines was interestingly in line with our bioinformatics gene analysis that identified deregulation of several CAM genes including ICAM1, ICAM2, ICAM3 and ICAM5. Studies in primary rat neurons have also described the involvement of CAMs in proper bundle formation. 39 In a more detailed investigation, we checked for neurite outgrowth during early stages of neuronal differentiation that refers to cellular extensions, including immature axons and dendrites. 40, 41 As expected our data revealed reduced neurite length in DCX-deficient spheres confirming previous studies. 37, 42 Reduced neurite outgrowth has also been reported in a TUBA1A mutation model of lissencephaly in spontaneously differentiating neurospheres. 43 Neurite growth is regulated by several factors, including secreted mitogens, cell adhesion molecules and repellent/adherence factors (e.g., SLIT and Robo). 44, 45 Hence, our findings of reduced neurite length overlaps in time with altered transcriptional expression of adhesion molecules, including CHL1 and upregulation of the repellent factor SLIT3. SLIT family have been reported to suppress process extensions in neural cell lines via inactivation of GSK3β. 46 Indeed, we were able to rescue the dampened neurite outgrowth in mutated DCX cells with both SLIT-3 knockdown and treatment with recombinant Robo1 and Robo2 proteins. SLIT-3 shRNA could reduce the repulsive response from excessive SLIT-3. Moreover, we applied recombinant Robo1 and Robo2 to sequester upregulated SLIT3 ligand, 47 which significantly increased neurite outgrowth in patient spheres. However, treatment with recombinant DCX significantly increased only control neurospheres neurite outgrowth. The effect of recombinant DCX on control neurospheres is in line with previous studies showing that overexpression of DCX induces microtubule bundling. 48, 49 There is also evidence showing recombinant wildtype DCX protein can increase the tubulin polymerization; however, using recombinant DCX-S47E protein (point mutation introduced to Ser-47) exhibited lower activity in facilitating tubulin polymerization and also microtubule bundling. 50 More importantly Tanaka et al. 50 showed that overexpression of mutated DCX (R89G, T203R, 303stop) do not have any effect on migration while overexpression of wild-type DCX increases migration rates, which is also supported by our observation. We can only speculate about the failure of recombinant DCX to fully rescue the neurite outgrowth of the patient neural cells; either the mutated DCX is sequestering the healthy recombinant DCX or the levels of DCX need to reach over a certain threshold to have a function, which we might not have reached.
Furthermore our patient cells remained in a proliferative state longer during differentiation, as shown by a slower loss of the proliferation marker Ki67 compared with healthy lines. This apparent initial resistance of patient NESCs to differentiate, combined with aberrant neurite outgrowth observations, suggests an important role for DCX when neural progenitor cells initiate differentiation and migration. These observations were confirmed also with our STRING analyze components showing Notch and SRC as central nodes for the six common genes. Notch signaling is required for maintenance of neural stem cells in proper embryonic and adult neurogenesis [52] [53] [54] [55] and SRC, the non-receptor tyrosine kinase, controls the cell growth and involved in neuronal development. 56, 57 Figure 5 shows a summarizing model of the cellular events we have observed in DCX mutated patient samples and their potential effects on brain development. Cell adhesion molecules are critical components in the correct guidance of migrating neural precursor cells, axonal guidance, synaptic formation and functional plasticity in the nervous system. 58 Several adhesion proteins, including ICAM1, ICAM5, and cadherins (CDH3, CDH4, CDH13, CDH15, CDH16, CDH17, CDH20, CDH22, CDH23, CDH24 and CDH26) were found to be deregulated in differentiating DCX mutated lines. Lack of cell adhesion molecules have been shown in other genetic-based lissencephaly such as mutation of RELN. 59 However, to our knowledge no previous study has suggested adhesion molecule deregulation in DCX-mutation lissencephaly. These data suggest that DCX-deficient cells failed to properly regulate expression of some key proteins required for glial fiberguided radial migration. We show that proper expression and function of DCX is critical for correct initiation and maintenance of Figure 5 . Schematic illustration of the cellular phenotype of DCXmutated neural cells. In early development, neural precursors are born and proliferate in the ventricular area of the brain. Neurogenesis begins when progenitor cells become post-mitotic and start migrating toward the cortical plate to build up six cortical layers. Cortical malformation in lissencephaly is known to be the result of aberrant neuronal migration during the early stages of neurogenesis. Here, we showed that lissencephaly-derived neural stem cells with impaired migration stay in the proliferation stage longer than control cells after growth factor withdrawal. Our data also indicated a delayed differentiation with shorter neurites emerging from patient cells compared with control cells. RG, radial glia; oRG, outer radial glia.
An in vitro model of lissencephalydifferentiation in addition to migration during neurogenesis ( Figure 5 ). The presented in vitro model provides a system that enables further detailed analysis of for example the link between migration and differentiation, which can be viewed as a 'hen and the egg' question. By using this in vitro system it would also be possible to in detail study how neural stem cells leave the stem cells state and initiate differentiation.
